The weight loss landscape is buzzing this year, thanks to some significant research progress on GLP-1 medications and various strategies. Experts in this field shared their forecasts for what we can expect by 2026.
Part 1: Transition to Holistic Treatment
Dr. Peter Balazs, a specialist in hormones and weight loss across New York and New Jersey, believes a key shift will be viewing GLP-1 drugs as “multisystem metabolic regulators” instead of merely “weight loss drugs.” This adjustment is, perhaps, a more comprehensive approach.
“The aim isn’t just to lower BMI anymore; it’s about reducing the overall cardiometabolic risks,” he explained, noting the positive impacts seen on organs like the liver, heart, and kidneys.
There have been noticeable reductions in severe cardiovascular incidents and the advancement of kidney disease as well.
Dr. Philip Rabito, another expert focusing on endocrinology and weight management in New York City, expressed optimism regarding upcoming advancements with GLP-1 and GIP medications. “The newer generation of drugs, especially when combined with glucagon and amylin agonists, could offer better weight loss outcomes than current treatments, along with improved tolerability and sustainability,” he mentioned.
He also hinted at exciting new federal collaborations with drug manufacturers aimed at increasing accessibility and affordability of these medications for those who need them most.
No. 2: More Convenient Administration
Typically, GLP-1 medications require weekly injections. However, Balazs anticipates that by 2026, there could be more user-friendly methods of administration. For instance, a 25 mg daily tablet version of Novo Nordisk’s Wegovy, which targets obesity, has been greenlit for long-term management, providing a non-injection alternative.
On top of that, a once-weekly oral version of GLP-1 is already in phase 2 trials, along with an implant set for three to six months of drug release.
Part 3: Minimally Invasive Surgery
Balazs also foresees non-incisional metabolic surgery becoming a preferred option due to its lower risk profile for GLP-1 users.
He pointed to endoscopic procedures like endoscopic sleeve gastroplasty, which reduces stomach size internally, and duodenal mucosal resurfacing, which helps manage blood sugar by resetting part of the small intestine. “These procedures could become more durable and widely accessible,” he predicted.
Rabito shared Balazs’ enthusiasm, stating that rapid developments in minimally invasive surgeries could present new avenues for patients wary of traditional bariatric surgery.
While bariatric surgery is still viewed as the most effective approach to treating obesity, offering significant and lasting weight loss, some patients may prefer these newer, less invasive options.
Part 4: Younger Users of GLP-1 Medications
With Novo Nordisk’s Wigoby now available for those aged 12 and over, the application of weight loss medications in younger populations is becoming a reality, according to Balazs. He anticipates that more alternatives specifically for younger patients may be approved by 2026.
No. 5: Technological and Personalized Approaches
As artificial intelligence continues to evolve, Balazs believes we’ll see broader integration of AI-driven weight loss strategies. This may include categorizing obesity into specific types like “hungry brain” or “emotional starvation,” moving beyond the old trial-and-error methods for personalized treatment.
Ghanem concurred, noting that there is likely to be a significant emphasis on understanding individual causes of obesity since it’s a complex issue that varies from person to person.
The expectation is that more patients will seek out combinations of treatments, showing increased awareness of different strategies available to tackle obesity.
Balazs also highlighted the rise of prescription digital therapies, which could further enhance weight loss options. These applications often combine cognitive behavioral therapy with personalized nutrition and real-time monitoring, potentially becoming part of reimbursed medical care.
In summary, as we look towards 2026, innovations in weight loss strategies—from medications to tech solutions—seem poised to reshape how obesity is tackled, offering more personalized and accessible modes of treatment.
